Published in Inflamm Bowel Dis on July 01, 2009
Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol (2010) 4.07
Toll-like receptor-4 inhibits enterocyte proliferation via impaired beta-catenin signaling in necrotizing enterocolitis. Gastroenterology (2009) 2.64
Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. J Clin Invest (2010) 2.48
Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis (2010) 1.79
NF-κB in the regulation of epithelial homeostasis and inflammation. Cell Res (2010) 1.72
Significance of heparanase in cancer and inflammation. Cancer Microenviron (2011) 1.46
An innately dangerous balancing act: intestinal homeostasis, inflammation, and colitis-associated cancer. J Exp Med (2010) 1.42
p120-catenin is essential for maintenance of barrier function and intestinal homeostasis in mice. J Clin Invest (2010) 1.41
New insights into the pathogenesis and treatment of necrotizing enterocolitis: Toll-like receptors and beyond. Pediatr Res (2011) 1.36
Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J Clin Invest (2011) 1.32
Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm Bowel Dis (2010) 1.28
Toll-like receptor 2 signaling protects mice from tumor development in a mouse model of colitis-induced cancer. PLoS One (2010) 1.26
The Yin and Yang of Toll-like receptors in cancer. Oncogene (2013) 1.23
The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models. J Gastroenterol (2012) 1.20
IKKβ in intestinal mesenchymal cells promotes initiation of colitis-associated cancer. J Exp Med (2015) 1.18
The struggle within: microbial influences on colorectal cancer. Inflamm Bowel Dis (2011) 1.15
Intracellular heat shock protein-70 negatively regulates TLR4 signaling in the newborn intestinal epithelium. J Immunol (2012) 1.15
Pathogen recognition receptors, cancer and inflammation in the gut. Curr Opin Pharmacol (2009) 1.14
Toll-like receptor 4 activation in cancer progression and therapy. Clin Dev Immunol (2011) 1.14
Toll-like receptor genes and their association with colon and rectal cancer development and prognosis. Int J Cancer (2011) 1.12
NADPH oxidases: an overview from structure to innate immunity-associated pathologies. Cell Mol Immunol (2014) 1.08
Tpl2 ablation promotes intestinal inflammation and tumorigenesis in Apcmin mice by inhibiting IL-10 secretion and regulatory T-cell generation. Proc Natl Acad Sci U S A (2012) 1.04
The dual role of inflammation in colon carcinogenesis. Int J Mol Sci (2012) 1.01
Innate immunity in the small intestine. Curr Opin Gastroenterol (2012) 1.01
Innate immunity in the small intestine. Curr Opin Gastroenterol (2011) 1.01
The role of pattern recognition receptors in intestinal inflammation. Mucosal Immunol (2013) 1.00
Mechanisms of gut barrier failure in the pathogenesis of necrotizing enterocolitis: Toll-like receptors throw the switch. Semin Pediatr Surg (2013) 0.98
Adenoma formation following limited ablation of p120-catenin in the mouse intestine. PLoS One (2011) 0.98
Comparison of oral microbiota in tumor and non-tumor tissues of patients with oral squamous cell carcinoma. BMC Microbiol (2012) 0.94
How the Intricate Interaction among Toll-Like Receptors, Microbiota, and Intestinal Immunity Can Influence Gastrointestinal Pathology. J Immunol Res (2015) 0.94
Epithelial barrier biology: good fences make good neighbours. Immunology (2012) 0.93
Toll-like receptor signaling and regulation of intestinal immunity. Virulence (2013) 0.91
Prognostic value of innate and adaptive immunity in colorectal cancer. World J Gastroenterol (2013) 0.90
Upregulation of TLRs and IL-6 as a marker in human colorectal cancer. Int J Mol Sci (2014) 0.87
Contribution of TLR signaling to the pathogenesis of colitis-associated cancer in inflammatory bowel disease. World J Gastroenterol (2014) 0.83
Urokinase-type plasminogen activator deficiency promotes neoplasmatogenesis in the colon of mice. Transl Oncol (2014) 0.82
Polymorphisms in NFKB1 and TLR4 and interaction with dietary and life style factors in relation to colorectal cancer in a Danish prospective case-cohort study. PLoS One (2015) 0.81
Role of microRNAs in resveratrol-mediated mitigation of colitis-associated tumorigenesis in Apc(Min/+) mice. J Pharmacol Exp Ther (2014) 0.80
Prebiotic treatment reduced preneoplastic lesions through the downregulation of toll like receptor 4 in a chemo-induced carcinogenic model. J Clin Biochem Nutr (2011) 0.80
Recent advancement in understanding colitis-associated tumorigenesis. Inflamm Bowel Dis (2014) 0.79
Messages from the Inside. The Dynamic Environment that Favors Intestinal Homeostasis. Front Immunol (2013) 0.79
Immunomodulation by gut microbiota: role of Toll-like receptor expressed by T cells. J Immunol Res (2014) 0.78
Intestinal Epithelial Toll-Like Receptor 4 Signaling Affects Epithelial Function and Colonic Microbiota and Promotes a Risk for Transmissible Colitis. Infect Immun (2016) 0.78
SIGIRR, a negative regulator of colon tumorigenesis. Drug Discov Today Dis Mech (2012) 0.77
Mechanisms of Immune Signaling in Colitis-Associated Cancer. Cell Mol Gastroenterol Hepatol (2014) 0.77
Extracts of Feijoa Inhibit Toll-Like Receptor 2 Signaling and Activate Autophagy Implicating a Role in Dietary Control of IBD. PLoS One (2015) 0.76
Mechanistic roles of epithelial and immune cell signaling during the development of colitis-associated cancer. Cancer Res Front (2016) 0.76
Toll-like receptor expression pattern: clinical application. J Clin Immunol (2012) 0.75
All-Trans Retinoic Acid Modulates TLR4/NF-κB Signaling Pathway Targeting TNF-α and Nitric Oxide Synthase 2 Expression in Colonic Mucosa during Ulcerative Colitis and Colitis Associated Cancer. Mediators Inflamm (2017) 0.75
Protective function of interleukin 27 in colitis-associated cancer via suppression of inflammatory cytokines in intestinal epithelial cells. Oncoimmunology (2017) 0.75
Distribution of bone-marrow-derived endothelial and immune cells in a murine colitis-associated colorectal cancer model. PLoS One (2013) 0.75
Vam3, a Compound Derived from Vitis amurensis Rupr., Attenuated Colitis-Related Tumorigenesis by Inhibiting NF-κB Signaling Pathway. Front Pharmacol (2016) 0.75
Apolipoprotein A-I inhibits experimental colitis and colitis-propelled carcinogenesis. Oncogene (2015) 0.75
Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell (2004) 29.32
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82
NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature (2004) 15.14
Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 14.55
Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature (1995) 10.36
The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut (2001) 10.07
Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc Natl Acad Sci U S A (2004) 5.89
Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun (2000) 5.65
Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest (2008) 5.26
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology (2004) 4.45
Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol (2005) 4.28
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 3.99
Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut (1988) 3.66
Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology (2007) 3.39
Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells. Gastroenterology (2004) 3.11
Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol (2005) 2.98
Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology (2002) 2.80
Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology (2006) 2.78
Myd88-dependent positioning of Ptgs2-expressing stromal cells maintains colonic epithelial proliferation during injury. J Clin Invest (2007) 2.55
The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. Immunity (2007) 2.44
NF-kappaB and cancer: mechanisms and targets. Mol Carcinog (2006) 2.40
Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J Clin Invest (2000) 2.27
Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol Med (2002) 2.24
Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology (2004) 2.23
Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut (1998) 2.14
Elimination of colon cancer in germ-free transforming growth factor beta 1-deficient mice. Cancer Res (2002) 2.12
Toll-like receptor 4 contributes to colitis development but not to host defense during Citrobacter rodentium infection in mice. Infect Immun (2006) 1.87
Chronic inflammation, apoptosis and (pre-)malignant lesions in the gastro-intestinal tract. Apoptosis (2004) 1.77
Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut (1994) 1.75
Dextran sulfate sodium-induced colitis-associated neoplasia: a promising model for the development of chemopreventive interventions. Acta Pharmacol Sin (2007) 1.68
Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate-induced colon carcinogenesis in mice. Carcinogenesis (2005) 1.65
Increased susceptibility to colitis-associated cancer of mice lacking TIR8, an inhibitory member of the interleukin-1 receptor family. Cancer Res (2007) 1.54
Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res (2003) 1.48
Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J Immunol (1992) 1.33
The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. Am J Pathol (2000) 1.27
Roles of myofibroblasts in prostaglandin E2-stimulated intestinal epithelial proliferation and angiogenesis. Cancer Res (2006) 1.19
Differential immunohistochemical detection of amphiregulin and cripto in human normal colon and colorectal tumors. Cancer Res (1992) 1.17
Recent data with anti-epidermal growth factor receptor antibodies and irinotecan in colon cancer. Clin Colorectal Cancer (2005) 1.16
TNF receptor type I-dependent activation of innate responses to reduce intestinal damage-associated mortality. Gastroenterology (2007) 1.11
Keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) chemokines and pro-inflammatory chemokine networks in mouse and human ovarian epithelial cancer cells. Cancer Biol Ther (2007) 1.09
Innate immune relationship between commensal flora and the mammalian intestinal epithelium. Cell Mol Life Sci (2005) 1.08
Macrophage infiltration and growth of sarcoma clones expressing different amounts of monocyte chemotactic protein/JE. Int J Cancer (1991) 1.02
Characterization of macrophage subpopulations in colon cancer using tissue microarrays. Histopathology (2005) 0.89
Regulation of Toll-like receptor 4 expression in mouse colon by macrophage migration inhibitory factor. Histochem Cell Biol (2005) 0.88
Innate immunity and mucosal bacterial interactions in the intestine. Curr Opin Gastroenterol (2004) 0.87
Cancer prevention in patients with inflammatory bowel disease. Gastroenterol Clin North Am (2002) 0.86
Association of different macrophage phenotypes with infiltrating and non-infiltrating areas of tumor-host interface in colorectal carcinoma. Pathol Res Pract (1994) 0.82
Comparison of the carcinogenicity of methylazoxymethanol-beta-D-glucosiduronic acid in conventional and germfree Sprague-Dawley rats. J Natl Cancer Inst (1981) 0.81
Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol (2005) 4.28
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 3.99
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med (2010) 3.53
Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med (2014) 2.98
Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut. J Immunol (2003) 2.96
Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology (2006) 2.78
6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology (2002) 2.35
Gremlin is the BMP antagonist required for maintenance of Shh and Fgf signals during limb patterning. Nat Genet (2003) 2.31
Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol (2003) 2.20
Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol (2008) 2.16
Beta-defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells. J Immunol (2004) 2.05
Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 2.04
6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology (2003) 1.95
Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol (2005) 1.93
Toll-like receptor signaling in small intestinal epithelium promotes B-cell recruitment and IgA production in lamina propria. Gastroenterology (2008) 1.89
Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol (2011) 1.88
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut (2011) 1.80
American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology (2006) 1.78
The myeloid differentiation factor 88 (MyD88) is required for CD4+ T cell effector function in a murine model of inflammatory bowel disease. J Immunol (2008) 1.75
Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus. Virology (2004) 1.73
Retracted A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A (2008) 1.69
A family of ductile intermetallic compounds. Nat Mater (2003) 1.66
Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders. Semin Immunol (2009) 1.66
Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials (2007) 1.62
GPR15-mediated homing controls immune homeostasis in the large intestine mucosa. Science (2013) 1.58
Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res (2011) 1.58
Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2012) 1.57
A genome-wide scan of Ashkenazi Jewish Crohn's disease suggests novel susceptibility loci. PLoS Genet (2012) 1.52
Defects in mucosal immunity leading to Crohn's disease. Immunol Rev (2005) 1.48
De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci (2006) 1.45
A decompositional approach to parameter estimation in pathway modeling: a case study of the Akt and MAPK pathways and their crosstalk. Bioinformatics (2006) 1.44
American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology (2006) 1.43
An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol (2011) 1.42
The impact of Hispanic ethnicity and race on post-surgical complications in patients with inflammatory bowel disease. Dig Dis Sci (2013) 1.40
A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol (2009) 1.39
Exercise attenuates PCB-induced changes in the mouse gut microbiome. Environ Health Perspect (2013) 1.33
Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm Bowel Dis (2007) 1.33
Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm Bowel Dis (2010) 1.28
Toll-like receptor 4 differentially regulates epidermal growth factor-related growth factors in response to intestinal mucosal injury. Lab Invest (2010) 1.23
NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology (2006) 1.20
Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol (2010) 1.19
Molecular genetics of hepatocellular neoplasia. Am J Transl Res (2010) 1.16
Stochastic roadmap simulation: an efficient representation and algorithm for analyzing molecular motion. J Comput Biol (2003) 1.15
An update on the molecular genetics of hepatocellular carcinoma. Semin Liver Dis (2004) 1.15
Molecular classification of soft tissue sarcomas and its clinical applications. Int J Clin Exp Pathol (2010) 1.15
Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 1.14
Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. Dig Dis Sci (2009) 1.14
Pathogen recognition receptors, cancer and inflammation in the gut. Curr Opin Pharmacol (2009) 1.14
Scalable GMP compliant suspension culture system for human ES cells. Stem Cell Res (2012) 1.14
Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology (2013) 1.14
Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost (2004) 1.12
Advances in the pathogenesis of inflammatory bowel disease. Curr Gastroenterol Rep (2006) 1.12
Evaluation of 22 genetic variants with Crohn's disease risk in the Ashkenazi Jewish population: a case-control study. BMC Med Genet (2011) 1.10
Mechanical unloading leads to echocardiographic, electrocardiographic, neurohormonal, and histologic recovery. J Heart Lung Transplant (2005) 1.10
TLR4 activates the β-catenin pathway to cause intestinal neoplasia. PLoS One (2013) 1.10
Intestinal trefoil factor: a marker of poor prognosis in gastric carcinoma. Clin Cancer Res (2002) 1.10
A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis (2004) 1.07
The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis (2004) 1.05
Replication-competent lentivirus analysis of clinical grade vector products. Mol Ther (2010) 1.04
Predictors of aggressive inflammatory bowel disease. Gastroenterol Hepatol (N Y) (2011) 1.02
Biomarkers in inflammatory bowel disease. Curr Opin Gastroenterol (2004) 1.01
Innate immunity in the small intestine. Curr Opin Gastroenterol (2012) 1.01
Innate immunity in the small intestine. Curr Opin Gastroenterol (2011) 1.01
Phenotypic manifestations of inflammatory bowel disease differ between Hispanics and non-Hispanic whites: results of a large cohort study. Am J Gastroenterol (2012) 1.00
Histologic characteristics of pancreatic intraepithelial neoplasia associated with different pancreatic lesions. Hum Pathol (2010) 0.99
Congenital disorder of glycosylation id presenting with hyperinsulinemic hypoglycemia and islet cell hyperplasia. J Clin Endocrinol Metab (2005) 0.99
Copy number and gene expression differences between African American and Caucasian American prostate cancer. J Transl Med (2010) 0.99
Ulcerative colitis therapy: importance of delivery mechanisms. Rev Gastroenterol Disord (2005) 0.98
Regulation of Toll-like receptor 4-associated MD-2 in intestinal epithelial cells: a comprehensive analysis. Innate Immun (2009) 0.97
Benign hybrid perineurioma-schwannoma in the colon. A case report. Ann Diagn Pathol (2006) 0.97
Microcarcinoids in large intestinal adenomas. Am J Surg Pathol (2006) 0.95
Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease. Inflamm Bowel Dis (2006) 0.94
Cancer in inflammatory bowel disease: lessons from animal models. Curr Opin Gastroenterol (2012) 0.93
The role of prostaglandin E2 (PGE 2) in toll-like receptor 4 (TLR4)-mediated colitis-associated neoplasia. BMC Gastroenterol (2010) 0.93
Co-expression of XIAP and cyclin D1 complex correlates with a poor prognosis in patients with hepatocellular carcinoma. Am J Pathol (2012) 0.93